Decision to list medical devices supplied by Atos Medical Limited and Halyard Australia Pty Limited

Hospital devices Decision

We are pleased to announce the approval of individual listing agreements with Atos Medical Limited and Halyard Australia Pty Limited Part III of Section H of the Pharmaceutical Schedule from 1 September 2018.

What we are doing



Atos Medical Limited (“Atos”)

  • Respiratory equipment and consumables devices (“Respiratory Care Products”)

Halyard Australia Pty Limited (“Halyard”)

  • Respiratory Care Products
  • Anaesthesia small equipment and consumable devices (“Anaesthesia Products”)

This will result in Pharmaceutical Schedule listings for 181 products from Atos and 66 products from Halyard.

Brand ranges in the Agreements include:

Respiratory care products


Halyard - Halyard

Anaesthesia products

Halyard - Microcuff

Any changes to the original proposal?

This decision was subject to consultation with a letter dated 26 June 2018.

No changes were made to the listing agreement as a result of consultation feedback.

Who we think will be most interested

  • Suppliers and Wholesalers
  • DHB Staff:
    • Clinical Engineers
    • Anaesthetists and Anaesthetic Technicians
    • Clinical staff involved with airway management and emergency respiratory resuscitation
    • Respiratory Clinicians
    • Respiratory therapists
    • Pulmonary function specialists
    • Pulmonary rehabilitation specialists
    • Clinical staff working in surgical and medical units, emergency departments, intensive and critical care units, and outpatient units
    • District nurses
    • Procurement Officers

Detail about this decision

In 2017 PHARMAC issued Requests for Proposals (“RFPs”) for respiratory care products and anaesthesia products. These RFPs were for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

After completing the RFP evaluation processes and consulting on the provisional Agreements reached with Atos and Halyard, PHARMAC has decided to list ranges of their medical devices in Part III of Section H of the Pharmaceutical Schedule.

The Atos and Halyard Respiratory Care Products will be available on PHARMAC's website from 1 September 2018, in both a PDF document and an Excel spreadsheet. The Halyard Anaesthesia Products will be available on the website from 1 March 2019.

DHB hospitals would continue to be able to choose which Anaesthesia Products and Respiratory Care Products they purchase, however would need to use these agreements should they choose to purchase Atos or Halyard Respiratory Care devices listed in the Pharmaceutical Schedule, effective from 1 September 2018.  

Although the Halyard Anaesthesia Products will not be listed in the Pharmaceutical Schedule until 1 March 2019, the pricing in the Agreement for these devices will be effective from the 1 September 2018.

Both of these companies have some products that are new to New Zealand DHBs and the Agreements would provide an increased range of devices from which clinicians could choose.

Pricing for Anaesthesia Products and Respiratory Care Products, subject to any prior termination of the Agreements, would not be increased without prior consultation and approval by PHARMAC.

Atos and Halyard will provide training and education services that will be tailored to suit the needs of individual DHBs in formats and at times as required by DHBs.

These are the first two Agreements for Respiratory Care Products and the ninth Agreement for Anaesthesia Products.

We intend to consult on proposed agreements for Anaesthesia Products and Respiratory Care Products with additional suppliers over the next few months.

Our response to what you told us

We appreciate the time people took to consider this consultation.

All consultation responses received by 17 July 2018 were considered in their entirety in making a decision to approve the Atos and Halyard provisional Agreements.

A summary of the main themes raised in feedback and our responses to the feedback received are set out below:


PHARMAC Staff Comment

Feedback that no technical or resource impacts are expected as a result of the proposal. 


If you have any questions about this decision, you can email us at; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.